{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Abnormalities&page=41",
    "query": {
      "condition": "Metabolic Abnormalities",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 2426,
    "total_pages": 243,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Abnormalities&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Abnormalities&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T11:49:54.299Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01183468",
      "title": "A Research Trial of Aralast in New Onset Diabetes (RETAIN)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Aralast NP 45 mg dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aralast NP 90 mg dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aralast NP 180 mg dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "8 Years to 35 Years"
      },
      "enrollment_count": 17,
      "start_date": "2010-10",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2018-06-13",
      "last_synced_at": "2026-10-31T11:49:54.299Z",
      "location_count": 15,
      "location_summary": "San Diego, California • Aurora, Colorado • New Haven, Connecticut + 10 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183468"
    },
    {
      "nct_id": "NCT07750678",
      "title": "Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Corneal Dystrophy",
        "Corneal Abnormality",
        "Corneal Dystrophies",
        "Corneal Dystrophies, Hereditary"
      ],
      "interventions": [
        {
          "name": "GEB-101 Injection",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "GenEditBio Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-10",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-31T11:49:54.299Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07750678"
    },
    {
      "nct_id": "NCT06056570",
      "title": "Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gout",
        "Hyperuricemia"
      ],
      "interventions": [
        {
          "name": "dotinurad",
          "type": "DRUG"
        },
        {
          "name": "dotinurad + allopurinol",
          "type": "DRUG"
        },
        {
          "name": "allopurinol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urica Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-10-04",
      "completion_date": "2024-07-09",
      "has_results": true,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-31T11:49:54.299Z",
      "location_count": 4,
      "location_summary": "Clearwater, Florida • Miami Lakes, Florida • Mesquite, Texas + 1 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Mesquite",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06056570"
    },
    {
      "nct_id": "NCT03533673",
      "title": "AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pompe Disease"
      ],
      "interventions": [
        {
          "name": "ACTUS-101",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "AskBio Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2018-12-17",
      "completion_date": "2026-03-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-31T11:49:54.299Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03533673"
    },
    {
      "nct_id": "NCT02330796",
      "title": "Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "Bucillamine",
          "type": "DRUG"
        },
        {
          "name": "Colchicine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revive Therapeutics, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 66,
      "start_date": "2015-04",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-10-05",
      "last_synced_at": "2026-10-31T11:49:54.299Z",
      "location_count": 3,
      "location_summary": "San Roman, California • Arlington, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "San Roman",
          "state": "California"
        },
        {
          "city": "Arlington",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02330796"
    },
    {
      "nct_id": "NCT01609062",
      "title": "Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mucopolysaccharidosis IVA",
        "Morquio A Syndrome",
        "MPS IVA"
      ],
      "interventions": [
        {
          "name": "BMN 110",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2012-04",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2016-02-01",
      "last_synced_at": "2026-10-31T11:49:54.299Z",
      "location_count": 4,
      "location_summary": "Oakland, California • Chicago, Illinois • New York, New York + 1 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01609062"
    },
    {
      "nct_id": "NCT04511702",
      "title": "Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Uncontrolled Gout",
        "Gout",
        "Uncontrolled Gout"
      ],
      "interventions": [
        {
          "name": "Pegloticase with MTX",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 191,
      "start_date": "2020-10-02",
      "completion_date": "2024-03-25",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-31T11:49:54.299Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04511702"
    },
    {
      "nct_id": "NCT01666080",
      "title": "Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hematologic Disorders",
        "Hemoglobinopathies",
        "Immunodeficiencies"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Stem cell transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Keppra",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-08",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-31T11:49:54.299Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01666080"
    },
    {
      "nct_id": "NCT04172441",
      "title": "Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Congenital Hyperinsulinism"
      ],
      "interventions": [
        {
          "name": "dasiglucagon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zealand Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Days",
        "maximum_age": "364 Days",
        "sex": "ALL",
        "summary": "7 Days to 364 Days"
      },
      "enrollment_count": 12,
      "start_date": "2020-06-19",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-10-31T11:49:54.299Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Fort Worth, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04172441"
    },
    {
      "nct_id": "NCT01663896",
      "title": "Observational Study of OCT in a Patients Undergoing FFR",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "OCT stent guidance",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 418,
      "start_date": "2012-12-11",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2020-07-02",
      "last_synced_at": "2026-10-31T11:49:54.299Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Orlando, Florida + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01663896"
    }
  ]
}